Protein Kinase CK2: New Perspectives of an Old Kinase
Novel, efficient at low micromolar concentrations, and selective CK2 inhibitors [1-7] has been recently designed by OTAVA Ltd., a leading Ukrainian company. To discover new inhibitors, company’s researchers spanned computer-based molecular modeling with chemical synthesis of compounds which were further tested in vitro to investigate their ability to bind to and affect the activity of CK2. The binding modes of inhibitors that target the ATP-binding site of CK2 were also studied. - September 26, 2008
Otava Ltd. and Institute of Genetics and Molecular Medicine at University of Edinburgh Announce Research Collaboration
Otava Ltd., a leading Ukrainian company that specializes in drug discovery technologies, and Institute of Genetics and Molecular Medicine at University of Edinburgh, Cancer Research UK-p53 Signal Transduction Laboratories (UK), have announced plans for an integrated research project focused on a... - March 02, 2008